Catheter-based delivery of cells to the heart

Warren Sherman, Timothy P. Martens, Juan Viles Gonzalez, Tomasz Siminiak

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Clinical trials have begun to assess the feasibility, safety, and efficacy of administering progenitor cells to the heart in order to repair or perhaps reverse the effects of myocardial ischemia and injury. In contrast to surgical-based injections, which are often coupled with coronary bypass surgery, catheter-based injections are less invasive and make it possible to evaluate cell products used as sole interventions. The two methods that have been tested in humans are injecting cells directly into the ventricular wall with catheter systems dedicated to that purpose and infusing cells into coronary arteries with standard balloon angioplasty catheters. The catheters described in this article have been shown in both animal and clinical studies to be effective in cell delivery and to be safe. They are well-designed and user-friendly devices, but require further investigation to identify means for optimizing cell retention and to address other limitations. Randomized, placebo-controlled trials utilizing catheters for cell implantation are under way, and others are soon to follow. The results of these studies will help to shape the direction of future investigations, both clinical and basic. The spectrum of cardiac diseases, the variety of catheters for cell delivery, and the wide array of progenitor cell types open up this young field to creative discoveries.

Original languageEnglish
JournalNature Clinical Practice Cardiovascular Medicine
Volume3
Issue numberSUPPL. 1
DOIs
StatePublished - Mar 1 2006
Externally publishedYes

Fingerprint

Catheters
Stem Cells
Injections
Balloon Angioplasty
Myocardial Ischemia
Heart Diseases
Coronary Vessels
Randomized Controlled Trials
Placebos
Clinical Trials
Safety
Equipment and Supplies
Wounds and Injuries

Keywords

  • Catheters
  • Cell delivery
  • Intracoronary
  • Intramyocardial
  • Progenitor cells

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Sherman, W., Martens, T. P., Viles Gonzalez, J., & Siminiak, T. (2006). Catheter-based delivery of cells to the heart. Nature Clinical Practice Cardiovascular Medicine, 3(SUPPL. 1). https://doi.org/10.1038/ncpcardio0446

Catheter-based delivery of cells to the heart. / Sherman, Warren; Martens, Timothy P.; Viles Gonzalez, Juan; Siminiak, Tomasz.

In: Nature Clinical Practice Cardiovascular Medicine, Vol. 3, No. SUPPL. 1, 01.03.2006.

Research output: Contribution to journalArticle

Sherman, W, Martens, TP, Viles Gonzalez, J & Siminiak, T 2006, 'Catheter-based delivery of cells to the heart', Nature Clinical Practice Cardiovascular Medicine, vol. 3, no. SUPPL. 1. https://doi.org/10.1038/ncpcardio0446
Sherman, Warren ; Martens, Timothy P. ; Viles Gonzalez, Juan ; Siminiak, Tomasz. / Catheter-based delivery of cells to the heart. In: Nature Clinical Practice Cardiovascular Medicine. 2006 ; Vol. 3, No. SUPPL. 1.
@article{35c0f74752444ca591cb2807eec6711e,
title = "Catheter-based delivery of cells to the heart",
abstract = "Clinical trials have begun to assess the feasibility, safety, and efficacy of administering progenitor cells to the heart in order to repair or perhaps reverse the effects of myocardial ischemia and injury. In contrast to surgical-based injections, which are often coupled with coronary bypass surgery, catheter-based injections are less invasive and make it possible to evaluate cell products used as sole interventions. The two methods that have been tested in humans are injecting cells directly into the ventricular wall with catheter systems dedicated to that purpose and infusing cells into coronary arteries with standard balloon angioplasty catheters. The catheters described in this article have been shown in both animal and clinical studies to be effective in cell delivery and to be safe. They are well-designed and user-friendly devices, but require further investigation to identify means for optimizing cell retention and to address other limitations. Randomized, placebo-controlled trials utilizing catheters for cell implantation are under way, and others are soon to follow. The results of these studies will help to shape the direction of future investigations, both clinical and basic. The spectrum of cardiac diseases, the variety of catheters for cell delivery, and the wide array of progenitor cell types open up this young field to creative discoveries.",
keywords = "Catheters, Cell delivery, Intracoronary, Intramyocardial, Progenitor cells",
author = "Warren Sherman and Martens, {Timothy P.} and {Viles Gonzalez}, Juan and Tomasz Siminiak",
year = "2006",
month = "3",
day = "1",
doi = "10.1038/ncpcardio0446",
language = "English",
volume = "3",
journal = "Nature Reviews Cardiology",
issn = "1759-5002",
publisher = "Nature Publishing Group",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Catheter-based delivery of cells to the heart

AU - Sherman, Warren

AU - Martens, Timothy P.

AU - Viles Gonzalez, Juan

AU - Siminiak, Tomasz

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Clinical trials have begun to assess the feasibility, safety, and efficacy of administering progenitor cells to the heart in order to repair or perhaps reverse the effects of myocardial ischemia and injury. In contrast to surgical-based injections, which are often coupled with coronary bypass surgery, catheter-based injections are less invasive and make it possible to evaluate cell products used as sole interventions. The two methods that have been tested in humans are injecting cells directly into the ventricular wall with catheter systems dedicated to that purpose and infusing cells into coronary arteries with standard balloon angioplasty catheters. The catheters described in this article have been shown in both animal and clinical studies to be effective in cell delivery and to be safe. They are well-designed and user-friendly devices, but require further investigation to identify means for optimizing cell retention and to address other limitations. Randomized, placebo-controlled trials utilizing catheters for cell implantation are under way, and others are soon to follow. The results of these studies will help to shape the direction of future investigations, both clinical and basic. The spectrum of cardiac diseases, the variety of catheters for cell delivery, and the wide array of progenitor cell types open up this young field to creative discoveries.

AB - Clinical trials have begun to assess the feasibility, safety, and efficacy of administering progenitor cells to the heart in order to repair or perhaps reverse the effects of myocardial ischemia and injury. In contrast to surgical-based injections, which are often coupled with coronary bypass surgery, catheter-based injections are less invasive and make it possible to evaluate cell products used as sole interventions. The two methods that have been tested in humans are injecting cells directly into the ventricular wall with catheter systems dedicated to that purpose and infusing cells into coronary arteries with standard balloon angioplasty catheters. The catheters described in this article have been shown in both animal and clinical studies to be effective in cell delivery and to be safe. They are well-designed and user-friendly devices, but require further investigation to identify means for optimizing cell retention and to address other limitations. Randomized, placebo-controlled trials utilizing catheters for cell implantation are under way, and others are soon to follow. The results of these studies will help to shape the direction of future investigations, both clinical and basic. The spectrum of cardiac diseases, the variety of catheters for cell delivery, and the wide array of progenitor cell types open up this young field to creative discoveries.

KW - Catheters

KW - Cell delivery

KW - Intracoronary

KW - Intramyocardial

KW - Progenitor cells

UR - http://www.scopus.com/inward/record.url?scp=33644623079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644623079&partnerID=8YFLogxK

U2 - 10.1038/ncpcardio0446

DO - 10.1038/ncpcardio0446

M3 - Article

C2 - 16501633

AN - SCOPUS:33644623079

VL - 3

JO - Nature Reviews Cardiology

JF - Nature Reviews Cardiology

SN - 1759-5002

IS - SUPPL. 1

ER -